MX2012007367A - Compuestos substituidos de imidazopiridinilo-aminopiridina. - Google Patents

Compuestos substituidos de imidazopiridinilo-aminopiridina.

Info

Publication number
MX2012007367A
MX2012007367A MX2012007367A MX2012007367A MX2012007367A MX 2012007367 A MX2012007367 A MX 2012007367A MX 2012007367 A MX2012007367 A MX 2012007367A MX 2012007367 A MX2012007367 A MX 2012007367A MX 2012007367 A MX2012007367 A MX 2012007367A
Authority
MX
Mexico
Prior art keywords
compounds
substituted imidazopyridinyl
aminopyridine compounds
aminopyridine
methods
Prior art date
Application number
MX2012007367A
Other languages
English (en)
Inventor
Shin Iimura
Yanbin Liu
Jason Hill
Rocio Palma
Jean-Marc Lapierre
Manish Tandon
David Vensel
Nivedita Namdev
Mark A Ashwell
Chris Brassard
Anton Filikov
Steffi Koerner
Robert Nicewonger
Akihisa Matsuda
Yuko Yamamoto
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of MX2012007367A publication Critical patent/MX2012007367A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)

Abstract

La presente invención se relaciona con compuestos sustituidos de imidazopiridinilo-aminopiridina y métodos para sintetizar estos compuestos. La presente invención también se relaciona con composiciones farmacéuticas que contienen compuestos sustituidos de imidazopiridinilo-aminopiridina y métodos para el tratamiento de trastornos celulares proliferativos, tales como cáncer, mediante la administración de estos compuestos y composiciones farmacéuticas a sujetos en necesidad de los mismos.
MX2012007367A 2009-12-30 2010-12-29 Compuestos substituidos de imidazopiridinilo-aminopiridina. MX2012007367A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29092309P 2009-12-30 2009-12-30
PCT/US2010/062440 WO2011082270A2 (en) 2009-12-30 2010-12-29 Substituted imidazopyridinyl-aminopyridine compounds

Publications (1)

Publication Number Publication Date
MX2012007367A true MX2012007367A (es) 2013-04-03

Family

ID=44227150

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007367A MX2012007367A (es) 2009-12-30 2010-12-29 Compuestos substituidos de imidazopiridinilo-aminopiridina.

Country Status (20)

Country Link
US (1) US8501770B2 (es)
EP (1) EP2519522B1 (es)
JP (1) JP5774602B2 (es)
KR (1) KR101689421B1 (es)
CN (1) CN102781940B (es)
AU (1) AU2010339533B2 (es)
BR (1) BR112012016398B1 (es)
CA (1) CA2785536C (es)
CO (1) CO6511271A2 (es)
DK (1) DK2519522T3 (es)
ES (1) ES2531109T3 (es)
IL (1) IL220571A (es)
MX (1) MX2012007367A (es)
MY (1) MY157124A (es)
NZ (1) NZ600801A (es)
PH (1) PH12012501323A1 (es)
RU (1) RU2619463C2 (es)
SG (1) SG181947A1 (es)
TW (1) TWI585086B (es)
WO (1) WO2011082270A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815854B2 (en) 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
KR20190015600A (ko) * 2011-06-24 2019-02-13 아르퀼 인코포레이티드 치환된 이미다조피리디닐-아미노피리딘 화합물
WO2013078254A1 (en) * 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
AU2013262578B2 (en) * 2012-05-17 2017-07-13 The University Of Chicago Fluorinated derivatives of 4-aminopyridine
US9617215B2 (en) 2012-05-17 2017-04-11 The University Of Chicago Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging
US10059663B2 (en) 2013-08-29 2018-08-28 Kyoto Pharmaceutical Industries, Ltd. Aromatic compound and use thereof
GB201321741D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
TWI662033B (zh) * 2014-03-24 2019-06-11 美商亞闊股份有限公司 製備３－（３－（４－（１－胺基環丁基）苯基）－５－苯基－３Ｈ－咪唑並［４，５－ｂ］吡啶－２－基）吡啶－２－胺之方法
ES2745156T3 (es) * 2014-04-22 2020-02-27 Arqule Inc Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido
EP3189036B1 (en) * 2014-09-05 2023-07-19 ArQule, Inc. Compositions and methods for treating proliferation disorders
CN105315161B (zh) * 2015-06-05 2017-08-04 厦门医学院 一类PKB/Akt抑制剂的关键中间体的制备方法
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
US11208478B2 (en) 2016-08-07 2021-12-28 The Wistar Institute Of Anatomy And Biology Methods of detecting and treating a tumor expressing pT346 PDK1
EP3709986B1 (en) 2017-11-14 2023-11-01 Merck Sharp & Dohme LLC Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CN111344287B (zh) 2017-11-14 2023-12-19 默沙东有限责任公司 作为吲哚胺2，3-双加氧酶(ido)抑制剂的新型取代的联芳基化合物
JP7640458B2 (ja) 2018-10-05 2025-03-05 アンナプルナ バイオ インコーポレイテッド Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
TWI904095B (zh) * 2019-07-25 2025-11-11 印度商裘拉德製藥私人有限公司 乙醯輔酶a合成酶短鏈2(acss2)之小分子抑制劑
JP7564888B2 (ja) * 2020-05-01 2024-10-09 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
CN114262322B (zh) * 2020-09-16 2026-01-06 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
IL301567A (en) * 2020-09-30 2023-05-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A compound as an AKT KINASE inhibitor
CN114315839B (zh) * 2020-09-30 2025-09-26 武汉人福创新药物研发中心有限公司 嘧啶二酮类化合物及其用途
WO2022250170A1 (en) 2021-05-28 2022-12-01 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
EP4422756A1 (en) 2021-10-29 2024-09-04 Gilead Sciences, Inc. Cd73 compounds
EP4486390A1 (en) * 2022-03-02 2025-01-08 Terremoto Biosciences, Inc Covalent modifiers of akt1 and uses thereof
WO2024064026A1 (en) * 2022-09-19 2024-03-28 Alterome Therapeutics, Inc. Akt1 modulators
CN120225521A (zh) * 2022-09-26 2025-06-27 亚特罗姆医疗公司 Akt1调节剂
WO2024102621A1 (en) * 2022-11-09 2024-05-16 Alterome Therapeutics, Inc. Akt1 modulators
WO2024107565A1 (en) * 2022-11-14 2024-05-23 Alterome Therapeutics, Inc. Akt1 modulators
AU2024225909A1 (en) * 2023-02-24 2025-07-31 Terremoto Biosciences, Inc. Covalent modifiers of akt1 and uses thereof
WO2025059469A1 (en) * 2023-09-15 2025-03-20 Atavistik Bio, Inc. Substituted aminopyridine compounds as akt inhibitors
WO2025059577A1 (en) * 2023-09-15 2025-03-20 Atavistik Bio, Inc. Substituted aminopyridine compounds for use as akt1 inhibitors
WO2025059562A1 (en) * 2023-09-15 2025-03-20 Atavistik Bio, Inc. Substituted aminopyridine compounds and methods of treating disease using same
TW202530213A (zh) 2023-10-13 2025-08-01 美商特瑞莫托生物科學股份有限公司 Ａｋｔ１之半胱胺酸共價修飾劑及其用途
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025128834A1 (en) * 2023-12-15 2025-06-19 Alterome Therapeutics, Inc. Akt1 modulators
WO2025188662A1 (en) * 2024-03-06 2025-09-12 Alterome Therapeutics, Inc. Akt1 modulators
WO2025188658A1 (en) * 2024-03-06 2025-09-12 Alterome Therapeutics, Inc. Akt1 modulators
WO2025207620A1 (en) * 2024-03-27 2025-10-02 Alterome Therapeutics, Inc. Akt1 modulators
TW202602874A (zh) * 2024-03-27 2026-01-16 美商亞特羅姆醫療公司 Akt1抑制劑及其鹽之固態形式
WO2025217330A1 (en) * 2024-04-10 2025-10-16 Terremoto Biosciences, Inc. Cysteine covalent modifiers of akt1 and uses thereof
WO2026035750A1 (en) * 2024-08-05 2026-02-12 Pivot Therapeutics, Inc. Inhibitors of akt and uses thereof
WO2026049331A1 (ko) * 2024-08-26 2026-03-05 이화여자대학교 산학협력단 신규한 이미다조피리딘 또는 이미다조피라진 유도체 및 이의 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3722992A1 (de) 1987-07-11 1989-01-19 Thomae Gmbh Dr K Neue imidazo-pyridine und purine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2002859C (en) 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0800391A1 (en) 1994-12-28 1997-10-15 Janssen Pharmaceutica N.V. Benzimidazoles as inhibitors of calcitriol metabolism
AU3538899A (en) 1998-04-30 1999-11-23 Nippon Chemiphar Co. Ltd. Condensed imidazole derivative and therapeutic agent for liver disease
JP2000344780A (ja) 1998-09-24 2000-12-12 Fuji Photo Film Co Ltd 新規ベンゾピラン化合物、発光素子材料及びそれを使用した発光素子
US6403588B1 (en) * 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
WO2001083481A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
GB0206861D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Medicaments
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
PT1499316E (pt) 2002-04-18 2008-06-30 Schering Corp Derivados de (1-4-piperidinil)benzimidazole úteis como antagonistas de histamina h3
GB0215293D0 (en) * 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
AR045134A1 (es) * 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
DE602004020073D1 (de) * 2003-08-21 2009-04-30 Osi Pharm Inc 3-substituierte imidazopyridinderivate als c-kit-inhibitoren
EP1960382A1 (en) 2005-11-03 2008-08-27 ChemBridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
US20070142369A1 (en) * 2005-12-21 2007-06-21 Margaret Van Heek Combination of an H3 antagonist/inverse agonist and an appetite suppressant
ES2336625T3 (es) * 2006-03-22 2010-04-14 Vertex Pharmaceuticals Incorporated Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos.
CN100398540C (zh) 2006-04-03 2008-07-02 大连理工大学 芳杂环基咪唑并萘酰亚胺类化合物及其应用
PT2054405E (pt) 2006-07-11 2013-12-24 Dae Woong Pharma Novos derivados de biaril benzoimidazol e composição farmacêutica que compreende os mesmos
CN101674827A (zh) 2007-03-02 2010-03-17 先灵公司 苯并咪唑衍生物及其使用方法
WO2009000413A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
CN101802129B (zh) 2007-10-17 2014-01-01 第一毛织株式会社 有机光电装置用新化合物及包括该化合物的有机光电装置
KR20090007347U (ko) 2008-01-16 2009-07-21 춘-치 왕 가속 페달 포지션 센서를 구비한 자동차용 연료 공급 기구

Also Published As

Publication number Publication date
CA2785536A1 (en) 2011-07-07
US8501770B2 (en) 2013-08-06
PH12012501323A1 (en) 2014-12-17
KR101689421B1 (ko) 2016-12-23
KR20120120271A (ko) 2012-11-01
BR112012016398A2 (pt) 2018-08-21
RU2619463C2 (ru) 2017-05-16
BR112012016398B1 (pt) 2021-12-21
AU2010339533A1 (en) 2012-07-12
EP2519522A4 (en) 2013-03-13
HK1177458A1 (en) 2013-08-23
TWI585086B (zh) 2017-06-01
SG181947A1 (en) 2012-07-30
IL220571A (en) 2015-03-31
DK2519522T3 (en) 2014-12-08
EP2519522A2 (en) 2012-11-07
NZ600801A (en) 2013-09-27
EP2519522B1 (en) 2014-09-24
CN102781940A (zh) 2012-11-14
US20110172203A1 (en) 2011-07-14
JP2013516419A (ja) 2013-05-13
RU2012132444A (ru) 2014-02-10
WO2011082270A3 (en) 2011-11-17
CA2785536C (en) 2018-02-27
ES2531109T3 (es) 2015-03-10
CN102781940B (zh) 2016-09-07
AU2010339533B2 (en) 2015-05-07
JP5774602B2 (ja) 2015-09-09
MY157124A (en) 2016-05-13
TW201132640A (en) 2011-10-01
WO2011082270A2 (en) 2011-07-07
CO6511271A2 (es) 2012-08-31

Similar Documents

Publication Publication Date Title
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
PH12012501337A1 (en) Substituted pyrrolo-aminopyrimidine compounds
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011082267A8 (en) Substituted triazolo-pyrazine compounds
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
WO2011082266A3 (en) Substituted heterocyclic compounds
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
MX2013011922A (es) Compuestos de benceno substituido.
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
PH12015500825A1 (en) Substituted benzene compounds
MX2012010434A (es) Compuestos y composiciones novedosas para atacar a las celulas madre del cancer.
PH12012501556A1 (en) Substituted naphthalenyl-pyrimidine compounds
PH12013500955A1 (en) Spiro-oxindole mdm2 antagonists
MX2015006152A (es) Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m.
IN2014KN02601A (es)
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
WO2012061342A3 (en) Substituted benzo-imidazo-pyrido-diazepine compounds
WO2011082271A3 (en) Substituted triazolo-pyrimidine compounds
WO2012088491A3 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
WO2011082269A3 (en) Substituted benzo-pyrimido-tetrazolo-diazepine compounds
MX2012007471A (es) Compuestos substituidos de pirrolo-aminopirimidina.
HK1186679A (en) Therapeutic peptide-polymer conjugates, particles, compositions, and related methods

Legal Events

Date Code Title Description
FG Grant or registration